Delisting risk
Silexion Therapeutics (SLXN)
Develops RNA-targeting treatment candidates for KRAS-mutated pancreatic cancer.
$0.3515
Pre-market+0.00 (+0.34%)
At close$0.3503(−5.35%)
Something off on this page? Send us feedback.
Next report
Nov 11, 2026
estimated · in 69 days
EPS estimate
−$9.10
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26May '26Aug '26Nov '26
Reported−$0.26−$4.32−$2.88−$23.85−$8.50−$0.85−$5.17Pending
Estimate−$3.30−$3.15−$3.40−$1.17−$12.90−$1.29−$21.20−$9.10
Surprise+92.1%−37.1%+15.3%−1,938.5%+34.1%+34.1%+75.6%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$9.10 | — | — |
| Aug 2026 | −$21.20 | −$5.17 | +75.6% |
| May 2026 | −$1.29 | −$0.85 | +34.1% |
| May 2026 | −$12.90 | −$8.50 | +34.1% |
| Mar 2026 | −$1.17 | −$23.85 | −1,938.5% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$9.10 | — | — | — | — | — | — |
| Aug 14, 2026 | −$21.20 | −$5.17 | +75.6% | — | — | — | −8.7% |
| May 15, 2026 | −$1.29 | −$0.85 | +34.1% | — | — | — | −5.2% |
| May 12, 2026 | −$12.90 | −$8.50 | +34.1% | — | — | — | −5.0% |
| Mar 17, 2026 | −$1.17 | −$23.85 | −1,938.5% | — | — | — | −1.9% |
The latest year is open to everyone — the 7 quarters behind it read with an account. Sign in | |||||||
| Nov 12, 2025 | |||||||
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 18, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 15, 2024 | |||||||